Sustained Efficacy of Second-line JAK Inhibitors in Patients with Rheumatoid Arthritis: Insights from the ANSWER Cohort

Strategic Insights -

A recent multicenter, retrospective study published in the journal Rheumatology has shed light on the sustained efficacy of second-line Janus kinase (JAK) inhibitors in patients with rheumatoid arthritis (RA). The study, conducted by researchers at Osaka University, analyzed data from an observational multicenter registry of patients with RA in Japan, encompassing 5900 treatment courses. The study aimed to evaluate differences in drug continuation rates and efficacy between first- and second-line use of biological DMARDs (bDMARDs) and JAK inhibitors (JAKi) after failure of the initial therapy.

Key Takeaways:

  • The study found that JAKi maintained continuation rates and efficacy in second-line treatment compared with first-line treatment, which is potentially advantageous over bDMARDs for patients with RA who require a change in initial therapy.
  • The study analyzed data from an observational multicenter registry of patients with RA in Japan, encompassing 5900 treatment courses.
  • The study used competing risk analysis to analyze the hazard ratios after adjusting for potential confounders.
  • The study found that, among TNF inhibitors, IL-6 inhibitors, CTLA4, and JAKi, only JAKi showed no significant difference in the cumulative incidence function (CIF) of first- and second-line treatments.
  • The study concluded that JAKi demonstrated similar efficacy as first- and second-line therapy, unlike other drugs.

Statistics:

  • The study analyzed data from 5900 treatment courses.
  • The study found that JAKi maintained continuation rates and efficacy in second-line treatment compared with first-line treatment.
  • The study used competing risk analysis to analyze the hazard ratios after adjusting for potential confounders.

Sources:

  • NewsRx. Findings on Rheumatoid Arthritis Reported by Investigators at Osaka University (Sustained Efficacy of Second-line Jak Inhibitors In Patients With Rheumatoid Arthritis: Insights From the Answer Cohort). Health & Medicine Week. May 23, 2025; p 1864.
  • Sustained Efficacy of Second-line Jak Inhibitors In Patients With Rheumatoid Arthritis: Insights From the Answer Cohort. Rheumatology, 2025.